Alembic pharmaceuticals Limited has announced the designation of Mr. Amit Nayak as Senior Management Personnel, effective 1st May, 2026. The pharmaceutical company informed stock exchanges about this organizational development in compliance with regulatory requirements under SEBI listing obligations.

Key Appointment Details

The company has designated Mr. Amit Nayak, who currently serves as Vice President - Commercial Excellence, as Senior Management Personnel. This designation represents a formal recognition of his role within the senior leadership structure of the organization.

Professional Background and Qualifications

Mr. Nayak brings substantial experience and strong educational credentials to his enhanced role within the company. His academic foundation combines technical expertise with management skills, positioning him well for senior leadership responsibilities.

Educational Qualifications

• Post Graduate Diploma in Management (PGDM) from IMT Ghaziabad (2013)
• B.Tech in Pharmaceutical Sciences from Institute of Chemical Technology (formerly UDCT), Mumbai University (2011)

Professional Experience

Mr. Nayak has accumulated 12 years of experience in driving commercial excellence through multiple specialized areas:

• Optimized sales operations
• Digital enablement initiatives
• Market insights and analysis
• Business development activities

His professional journey includes associations with several prominent organizations in the pharmaceutical and consulting sectors, including J B Chemicals & Pharmaceuticals Ltd., Cipla Limited, IMS and EY.

Regulatory Compliance

The appointment notification was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Alembic Pharmaceuticals submitted the required details to both BSE Limited and National Stock Exchange of India Ltd., ensuring full compliance with disclosure requirements for senior management changes.

The company provided comprehensive information as mandated under the SEBI regulations, including detailed background information and the terms of the designation. The disclosure confirms that there are no relationships between directors that require separate notification under the regulatory framework.

Alembic Pharmaceuticals Limited has announced the schedule for its post-results conference call to discuss Q4FY26 quarterly and FY26 annual audited financial results. The pharmaceutical company informed stock exchanges on April 29, 2026 about the upcoming investor interaction scheduled for Friday, May 15, 2026.

Conference Call Details

The conference call is scheduled exclusively for analysts and institutional investors and will commence at 5:00 PM IST on Friday, May 15, 2026. The session will focus on discussing the company's Q4FY26 quarterly results and FY26 annual audited financial results.

Management Participation

The company's senior management team will represent Alembic Pharmaceuticals during the conference call. The management team includes key executives who will provide insights into the company's financial performance and business developments.

Participation Options

Alembic Pharmaceuticals has provided two convenient options for participants to join the conference call. The first option involves a Diamond Pass registration system that eliminates waiting time for operator assistance. Participants can register through the provided link and will receive dial-in numbers, passcode, and pin via email.

The second option offers traditional conference dial-in access with multiple contact numbers:

Contact Information

For additional information regarding the conference call, participants can contact Mr. Ajay Kumar Desai at phone numbers +91 22 66953681 or 7045504460, or via email at ajay.desai@alembic.co.in . The company secretary Manisha Saraf signed the official communication to the stock exchanges on April 29, 2026.